Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Treatment Period	STARTED	Active Control	32
Treatment Period	STARTED	Burosumab	29
Treatment Period	Completed Week 40	Active Control	32
Treatment Period	Completed Week 40	Burosumab	29
Treatment Period	Completed Week 64	Active Control	32
Treatment Period	Completed Week 64	Burosumab	29
Treatment Period	COMPLETED	Active Control	32
Treatment Period	COMPLETED	Burosumab	29
Treatment Period	NOT COMPLETED	Active Control	0
Treatment Period	NOT COMPLETED	Burosumab	0
Long Term Extension Period	STARTED	Active Control	26
Long Term Extension Period	STARTED	Burosumab	25
Long Term Extension Period	COMPLETED	Active Control	26
Long Term Extension Period	COMPLETED	Burosumab	25
Long Term Extension Period	NOT COMPLETED	Active Control	0
Long Term Extension Period	NOT COMPLETED	Burosumab	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02915705/flow